The Malaysian Reserve

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

LYMPHIR now available nationwideCRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") ...

GSE Solutions Market Analysis and Insights 2025: Trends, Opportunities, and Forecasts-PW Consulting

The rapid transformation of the aviation industry has placed unprecedented emphasis on operational efficiency, safety, and sustainability. In addressing these challenges, ground support equipment (GSE ...
Le Lézard

Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Citius Oncology, Inc. ("Citius Oncology") , the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today announced the commercial launch of LYMPHIRtm (denileukin ...
Le Lézard

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

AbbVie today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including ? multiple ...